Headlines about Minerva Neurosciences (NASDAQ:NERV) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Minerva Neurosciences earned a news impact score of 0.12 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 47.3725103521346 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Minerva Neurosciences (NASDAQ NERV) traded down 2.46% during trading on Friday, reaching $5.95. 137,657 shares of the company’s stock were exchanged. The firm’s market capitalization is $252.93 million. The stock has a 50-day moving average price of $7.59 and a 200 day moving average price of $8.26. Minerva Neurosciences has a 52 week low of $5.85 and a 52 week high of $14.92.
Minerva Neurosciences (NASDAQ:NERV) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.07. During the same period last year, the company posted ($0.18) earnings per share. Equities research analysts forecast that Minerva Neurosciences will post ($1.19) earnings per share for the current fiscal year.
Several research firms recently issued reports on NERV. Zacks Investment Research upgraded shares of Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.50 target price for the company in a research note on Wednesday, August 9th. BidaskClub cut shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. JMP Securities reiterated an “outperform” rating and issued a $20.00 target price (up from $17.00) on shares of Minerva Neurosciences in a research note on Thursday, June 1st. Finally, ValuEngine cut shares of Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research note on Monday, May 29th. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. Minerva Neurosciences presently has an average rating of “Hold” and an average target price of $14.83.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://stocknewstimes.com/2017/08/19/minerva-neurosciences-nerv-receives-coverage-optimism-rating-of-0-12.html.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.
